Harrow Health (NASDAQ:HROW) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $10.75 for the company and are expecting that the company will post $0.12 earnings per share for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 153 out of 255 based on the ratings given to related companies.
HROW has been the topic of several research reports. Zacks Investment Research lowered Harrow Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. ValuEngine lowered Harrow Health from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th.
Shares of HROW traded down $0.20 during mid-day trading on Friday, hitting $4.37. The stock had a trading volume of 198,897 shares, compared to its average volume of 244,119. The firm has a market cap of $107.90 million, a PE ratio of 7.16 and a beta of 0.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.76 and a quick ratio of 2.61. Harrow Health has a 52 week low of $1.99 and a 52 week high of $7.20.
Harrow Health (NASDAQ:HROW) last issued its earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.84 by ($0.07). The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $10.92 million. Harrow Health had a net margin of 35.35% and a return on equity of 177.27%. Sell-side analysts anticipate that Harrow Health will post -0.02 earnings per share for the current fiscal year.
In other Harrow Health news, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $5.86, for a total value of $58,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 30,000 shares of company stock worth $175,400. Corporate insiders own 13.78% of the company’s stock.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Featured Story: Float
Get a free copy of the Zacks research report on Harrow Health (HROW)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.